Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).
Phipps AI, Shi Q, Zemla TJ, Dotan E, Gill S, Goldberg RM, Hardikar S, Jahagirdar B, Limburg PJ, Newcomb PA, Shields A, Sinicrope FA, Sargent DJ, Alberts SR. Phipps AI, et al. Among authors: zemla tj. Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):696-703. doi: 10.1158/1055-9965.EPI-17-0769. Epub 2018 Mar 21. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 29563133 Free PMC article. Clinical Trial.
Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).
Song M, Ou FS, Zemla TJ, Hull MA, Shi Q, Limburg PJ, Alberts SR, Sinicrope FA, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Chan AT. Song M, et al. Among authors: zemla tj. Int J Cancer. 2019 Jul 15;145(2):380-389. doi: 10.1002/ijc.32113. Epub 2019 Jan 28. Int J Cancer. 2019. PMID: 30623420 Free PMC article. Clinical Trial.
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Innocenti F, et al. Among authors: zemla tj. J Clin Oncol. 2019 May 10;37(14):1217-1227. doi: 10.1200/JCO.18.01798. Epub 2019 Mar 13. J Clin Oncol. 2019. PMID: 30865548 Free PMC article.
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Lenz HJ, et al. J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1. J Clin Oncol. 2019. PMID: 31042420 Free PMC article. Clinical Trial.
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Abou-Alfa GK, et al. JAMA Oncol. 2019 Nov 1;5(11):1582-1588. doi: 10.1001/jamaoncol.2019.2792. JAMA Oncol. 2019. PMID: 31486832 Free PMC article.
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Chakrabarti S, et al. Among authors: zemla tj. Oncologist. 2020 May;25(5):380-e763. doi: 10.1634/theoncologist.2019-0874. Epub 2019 Dec 11. Oncologist. 2020. PMID: 31826977 Free PMC article. Clinical Trial.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Meyerhardt JA, et al. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. JAMA. 2021. PMID: 33821899 Free PMC article. Clinical Trial.
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
Brown JC, Ma C, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, Lewis D, Tan B, Krishnamurthi S, O'Reilly EM, Shields AF, Meyerhardt JA. Brown JC, et al. J Clin Oncol. 2023 Jan 10;41(2):243-254. doi: 10.1200/JCO.22.00171. Epub 2022 Aug 9. J Clin Oncol. 2023. PMID: 35944235 Free PMC article. Clinical Trial.
Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
Sinicrope FA, Shi Q, Catteau A, Poage GM, Zemla TJ, Mlecnik B, Benson AB, Gill S, Goldberg RM, Kahlenberg MS, Nair SG, Shields AF, Smyrk TC, Galon J, Alberts SR. Sinicrope FA, et al. Among authors: zemla tj. JCO Precis Oncol. 2022 Aug;6:e2200010. doi: 10.1200/PO.22.00010. JCO Precis Oncol. 2022. PMID: 35952316 Free PMC article. Clinical Trial.
45 results